A Phase 2 interventional study of XEN1101 10 mg and XEN1101 20 mg in Major Depressive Disorder, sponsored by Xenon Pharmaceuticals Inc.. Completed at 20 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by Xenon Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 259 under way, 27 of them phase 3. Depressive Disorder, Major · United States.
Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 410th largest by enrollment of the 1,323 interventional ones that give a count, is one of 52 that started in 2022, is one of 271 in phase 2, and was the 1,181st registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 22–60
Baylor College of Medicine · Sites in United States
Ages 18–64
Ohio State University · Sites in United States
Ages 21–65
Florida State University · Sites in United States
Ages 18–55 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,500 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 135 · Phase 2 325 · Phase 3 262 · Phase 4 189
First in 1979; this study’s year is marked. 52 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 168 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 70 across the 1,323 interventional studies, 100 across the 171 observational. Of the 1,156 that completed or were terminated, 584 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
484 of 1,500 have an industry lead sponsor. The 10 most frequent:
Xenon Pharmaceuticals Inc. is the lead sponsor of 23 studies on the registry; 3 are open to participants now.
Xenon Pharmaceuticals Inc. has 4 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
99 of the studies in Depressive Disorder, Major with a site in United States that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559306Phase 3Janssen Research & Development, LLCPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | 2026-12-30 |
| NCT06922110Phase 3Xenon Pharmaceuticals Inc.An Open-Label Study of Azetukalner in Major Depressive Disorder | 2027-01 |
| NCT04041479Phase 3Weill Medical College of Cornell UniversityBiomarker-guided rTMS for Treatment Resistant Depression | 2027-04 |
| NCT05850689Phase 3Intra-Cellular Therapies, Inc.Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | 2027-04-05 |
| NCT07076407Phase 3Xenon Pharmaceuticals Inc.A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | 2027-05 |
Add all 99 to your calendar (.ics) → With an account.
Among the 1,500 studies in Depressive Disorder, Major with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, Phase 2, double-blind, randomized, parallel-arm, placebo-controlled clinical trial to evaluate the efficacy, safety, and tolerability of XEN1101 in subjects with Major Depressive Disorder.
The study is divided into 3 stages: Screening - up to 4 weeks duration; Treatment - 6 weeks duration; Follow-up - 4 weeks duration. The total study duration per subject is estimated to be approximately 14 weeks.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During the double blind treatment period (42 days), subjects will take 1 capsule of XEN1101 10 mg, orally with food, per day
Drug: XEN1101 10 mg
During the double blind treatment period (42 days), subjects will take 1 capsule of XEN1101 20 mg, orally with food, per day
Drug: XEN1101 20 mg
During the double blind treatment period (42 days), subjects will take 1 capsule of placebo, orally with food, per day
Drug: Placebo
XEN1101 oral capsule
XEN1101 oral capsule
Placebo capsule
Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Score.
Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-rated, 10-item scale used to assess the severity of depressive symptoms. Each item is scored from 0 (normal/absent) to 6 (severe), yielding a total score ranging from 0 to 60, with higher scores indicating greater depression severity. MADRS total score change from baseline at week 6.
Time frame: From baseline to end of treatment (Week 6).
Change in Snaith-Hamilton Pleasure Scale (SHAPS) Score.
Snaith-Hamilton Pleasure Scale (SHAPS) is a validated 14-item self-report questionnaire commonly used to assess anhedonia (reduced ability to experience pleasure). Each of the 14 items is rated from 1 (strongly agree) to 4 (strongly disagree). Total scores range from 14 to 56, with higher scores indicating greater levels of anhedonia. SHAPS total score change from baseline at week 6
Time frame: From baseline to end of treatment (Week 6).
Change in Beck Anxiety Inventory (BAI) Score.
Beck Anxiety Inventory (BAI) is a 21-item self-report questionnaire used to assess the severity of anxiety symptoms. Each item is scored on a scale from 0 (not at all) to 3 (severely), yielding a total score ranging from 0 to 63, with higher scores indicating greater anxiety severity. BAI total score change from baseline at week 6
Time frame: From baseline to end of treatment (Week 6).
| Milestone | Placebo | Azetukalner (XEN1101) 10 mg | Azetukalner (XEN1101) 20 mg |
|---|---|---|---|
| Started | 56 | 56 | 56 |
| Safety population | 55 | 56 | 56 |
| Modified intent-to-treat (mitt) population | 54 | 55 | 55 |
| Completed | 47 | 50 | 46 |
| Not completed | 9 | 6 | 10 |
Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-rated, 10-item scale used to assess the severity of depressive symptoms. Each item is scored from 0 (normal/absent) to 6 (severe), yielding a total score ranging from 0 to 60, with higher scores indicating greater depression severity. MADRS total score change from baseline at week 6.
| MADRS total score | Placebo | Azetukalner (XEN1101) 10 mg | Azetukalner (XEN1101) 20 mg |
|---|---|---|---|
| Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Score. | -13.90 ± 1.41 | -15.61 ± 1.34 | -16.94 ± 1.45 |
Snaith-Hamilton Pleasure Scale (SHAPS) is a validated 14-item self-report questionnaire commonly used to assess anhedonia (reduced ability to experience pleasure). Each of the 14 items is rated from 1 (strongly agree) to 4 (strongly disagree). Total scores range from 14 to 56, with higher scores indicating greater levels of anhedonia. SHAPS total score change from baseline at week 6
| Change in SHAPS total score | Placebo | Azetukalner (XEN1101) 10 mg | Azetukalner (XEN1101) 20 mg |
|---|---|---|---|
| Change in Snaith-Hamilton Pleasure Scale (SHAPS) Score. | -5.30 ± 0.85 | -6.71 ± 0.81 | -7.77 ± 0.87 |
Beck Anxiety Inventory (BAI) is a 21-item self-report questionnaire used to assess the severity of anxiety symptoms. Each item is scored on a scale from 0 (not at all) to 3 (severely), yielding a total score ranging from 0 to 63, with higher scores indicating greater anxiety severity. BAI total score change from baseline at week 6
| Change in BAI total score | Placebo | Azetukalner (XEN1101) 10 mg | Azetukalner (XEN1101) 20 mg |
|---|---|---|---|
| Change in Beck Anxiety Inventory (BAI) Score. | -6.27 ± 0.91 | -7.27 ± 0.86 | -6.94 ± 0.94 |
Collected over 10 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/55 (0%) | 2/55 (3.6%) | 15/55 (27.3%) |
| Azetukalner (XEN1101) 10 mg | 0/56 (0%) | 0/56 (0%) | 18/56 (32.1%) |
| Azetukalner (XEN1101) 20 mg | 0/56 (0%) | 0/56 (0%) | 31/56 (55.4%) |
| Event | Placebo | Azetukalner (XEN1101) 10 mg | Azetukalner (XEN1101) 20 mg |
|---|---|---|---|
| Idiopathic intracranial hypertensionNervous system disorders | 1/55 | 0/56 | 0/56 |
| Homicidal ideationPsychiatric disorders | 1/55 | 0/56 | 0/56 |
| Event | Placebo | Azetukalner (XEN1101) 10 mg | Azetukalner (XEN1101) 20 mg |
|---|---|---|---|
| DizzinessNervous system disorders | 4/55 | 4/56 | 10/56 |
| HeadacheNervous system disorders | 7/55 | 5/56 | 5/56 |
| SomnolenceNervous system disorders | 1/55 | 6/56 | 6/56 |
| Disturbance in attentionNervous system disorders | 0/55 | 0/56 | 5/56 |
| DepressionPsychiatric disorders | 2/55 | 3/56 | 2/56 |
| ParaesthesiaNervous system disorders | 1/55 | 0/56 | 3/56 |
| Age, Continuous(Years) | Placebo | Azetukalner (XEN1101) 10 mg | Azetukalner (XEN1101) 20 mg | Total |
|---|---|---|---|---|
| Mean | 47.5 ± 12.7 | 47.4 ± 14.6 | 46.6 ± 13.8 | 47.2 ± 13.6 |
| Sex: Female, Male(Participants) | Placebo | Azetukalner (XEN1101) 10 mg | Azetukalner (XEN1101) 20 mg | Total |
|---|---|---|---|---|
| Female | 37 | 44 | 30 | 111 |
| Male | 18 | 12 | 26 | 56 |
| Race/Ethnicity, Customized(Participants) | Placebo | Azetukalner (XEN1101) 10 mg | Azetukalner (XEN1101) 20 mg | Total |
|---|---|---|---|---|
| Asian | 1 | 2 | 2 | 5 |
| Black or African American | 16 | 22 | 20 | 58 |
| White or Caucasian | 37 | 32 | 32 | 101 |
| Multiracial | 1 | 0 | 2 | 3 |
| Region of Enrollment(participants) | Placebo | Azetukalner (XEN1101) 10 mg | Azetukalner (XEN1101) 20 mg | Total |
|---|---|---|---|---|
| United States | 55 | 56 | 56 | 167 |
| MADRS total score at baseline(MADRS baseline score) | Placebo | Azetukalner (XEN1101) 10 mg | Azetukalner (XEN1101) 20 mg | Total |
|---|---|---|---|---|
| Mean | 34.5 ± 4.6 | 34.2 ± 4.8 | 33.1 ± 5.8 | 33.9 ± 5.1 |
| SHAPS total score at baseline(SHAPS baseline score) | Placebo | Azetukalner (XEN1101) 10 mg | Azetukalner (XEN1101) 20 mg | Total |
|---|---|---|---|---|
| Mean | 35.3 ± 5.6 | 36.8 ± 5.4 | 37.5 ± 6.3 | 36.5 ± 5.8 |
| BAI total score at baseline(BAI baseline score) | Placebo | Azetukalner (XEN1101) 10 mg | Azetukalner (XEN1101) 20 mg | Total |
|---|---|---|---|---|
| Mean | 13.5 ± 8.3 | 12.5 ± 9.1 | 14.9 ± 13.6 | 13.6 ± 10.6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2022 to primary completion in Sep 2023, 15 months.
Results were first posted in Sep 2026, 3 years after primary completion. A results delay was requested in Sep 2024.
Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 15 months is below that.
Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: XEN1101